Genomics & Diagnostics

The question

Are genomics-and-diagnostics franchises priced for a continued flat-to-declining capital-equipment cycle and a slow MRD ramp, or for the more likely outcome in which instrument utilization re-accelerates into 2026-2027 and minimal-residual-disease testing clears reimbursement hurdles in at least two major solid-tumor indications?

Base rates

Healthcare has trailed SPY by a meaningful margin over the trailing twelve months; inside healthcare, tools-and-diagnostics has been the worst-performing subsegment over the trailing twenty-four months, with the Illumina-Twist peer group down roughly fifty to seventy percent from 2021 peaks. That dislocation is the thesis. The relevant reference class is prior capex-cycle resets in instrument-driven businesses: the semiconductor capital-equipment trough of 2001-2003, the life-science-tools reset of 2013-2014, and the post-pandemic biopharma-equipment digestion of 2022-2024. In each case, consumables growth troughed six to twelve months after instrument growth, and the re-acceleration in consumables led instrument orders by roughly two quarters.

For MRD specifically, the base rate for a novel diagnostic category moving from Medicare-covered in one indication to Medicare-covered across three or more indications, conditional on published positive utility data, is roughly eighteen to thirty months. The current window fits that pattern. The conditional probability of reimbursement expansion to colorectal, breast, and non-small-cell lung by end-2027 is materially higher than the street's implied probability.

For the basket, median forward EV/sales sits at a twelve-year low, and the percentage of holdings trading below twelve-month trailing high-water-mark enterprise value is the highest since 2013. Those conditions have historically preceded above-average three-year returns for a diversified tools-and-diagnostics basket.

Why consensus is wrong

The sell-side is modeling instrument growth as the binding driver and extrapolating the 2023-2024 utilization trough forward. Three pieces of that view do not hold.

First, the sequencing cost curve has resumed its decline after roughly eighteen months of plateau. Illumina's NovaSeq X and PacBio's Revio production ramps have pushed per-genome cost below two-hundred dollars at scale, a threshold that historically precedes an acceleration in population-screening and MRD applications. The expectations embedded in consumables forecasts do not yet reflect the implied volume curve.

Second, MRD reimbursement has already cleared in colorectal under the MolDX framework and is on a visible path in breast and muscle-invasive bladder. Each incremental indication roughly doubles the addressable covered-lives pool; the consensus model applies linear ramps where the empirical pattern is step-function.

Third, the biopharma-services cohort absorbed an inventory digestion that is now largely complete, based on the combination of distributor reports, freight data, and direct-materials commentary from instrument makers. Consumables re-acceleration is the highest-conviction call inside the idea, and it has no dependence on any single reimbursement decision.

Position construction

The book has two twenty-percent anchors and three sub-books.

Anchors. Veeva at twenty percent is the life-sciences-software quality compounder and the highest-conviction defensive position in the book -- CRM and Vault platforms continue to compound through the cycle at high single-digit growth. Qiagen at twenty percent is the molecular-diagnostics instrument and consumables franchise at a post-reset multiple with intact operating margins.

Sequencing and MRD, roughly thirty-two percent. Guardant Health at ~17.2% is the purest MRD-expansion read through the Shield colorectal launch and the Reveal franchise. Arrowhead at ~10.7% is the siRNA-platform exposure with HELIOS-B cardiovascular outcomes data setting up a clean re-rating path. Pacific Biosciences at ~1.0% adds the long-read sequencing option at a distressed valuation. Veracyte at ~6.0% captures the thyroid, prostate, and pulmonary nodule Afirma and Decipher franchises. Adaptive Biotechnologies at ~5.2% is the clonoSEQ MRD position in hematologic malignancies.

Tools and instruments, roughly sixteen percent. Bruker at ~11.9% is the mass-spectrometry and single-cell franchise with the cleanest operating-margin profile in the tools cohort. Twist Bioscience at ~3.6% is the synthetic-DNA position at a post-capex-reset valuation. CareDx at ~1.6% adds transplant-diagnostics.

Specialty and asymmetric, roughly three percent. Ginkgo Bioworks at ~1.6%, Arcturus at ~1.2% are the most speculative positions in the book, sized to reflect execution risk.

Asymmetric payoff

If instrument utilization re-accelerates in 2026 and MRD reimbursement expands into two additional indications by mid-2027, the book returns roughly 16-28% annualized over three years as the multiple compression reverses. If utilization remains flat and MRD expansion slips past 2028, the book returns -5% to +5% with Veeva and Qiagen absorbing most of the drawdown. If the sequencing cost curve decline triggers a broad consumables re-acceleration, the right tail is 32-45%.

At a 50% base, 30% bear, 20% bull weighting, expected value is roughly +10 to +16% annualized against an SPY base rate near +8%. The asymmetry is pronounced because the tools cohort trades as if the bear case is already the base case.

Three things that would change our mind

1. MolDX or CMS issuing a non-coverage determination on MRD in breast or non-small-cell lung on utility grounds, which would signal the reimbursement path we are betting on has structural rather than administrative obstacles.
2. Consumables growth at Illumina, Bio-Rad, and Thermo tracking below three percent year-over-year for two consecutive quarters, indicating the utilization re-acceleration we expect is not materializing on the two-quarter lead we model.
3. A durable reset of NIH and academic research funding by more than fifteen percent that flows through to instrument and consumables demand, which would break the cyclical recovery thesis.

What we're explicitly NOT betting on

We are not betting on Illumina specifically -- the governance and strategic overhang is its own situation and is deliberately excluded from the book. We are not betting on a specific M&A target. We are not betting on liquid-biopsy multi-cancer screening clearing FDA or reimbursement on any particular timeline. We are not betting on CRISPR-based therapeutics re-rating; that is a separate thesis with different reference classes. The thesis requires only that instrument utilization recovers on a normal post-reset pattern, that consumables re-accelerate on the historical two-quarter lead, and that MRD expands into two additional indications within the visible reimbursement window. All three are testable and partially observable today.